FDA’s upcoming advisory committee review of Roche/Genentech Inc.’s Perjeta for a new indication in neoadjuvant breast cancer will help lead the way for approvals of drugs in early treatment, a new paradigm for oncology drug development.
The Oncologic Drugs Advisory Committee will meet Sept. 12 to consider a supplemental BLA for Perjeta (pertuzumab) in patients with...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?